NuGen Medical Devices Inc. specializes in developing innovative drug delivery technologies across various international markets. The company shows strong liquidity with a current ratio of 4.18, indicating good short-term financial health. However, it faces significant concerns with a gross margin of 60.9% contrasted by extremely negative EBITDA and net margins, suggesting operational inefficiencies. The low stock price of $0.01 and a market cap of $3.41M raise questions about its valuation despite promising technology. Overall, while liquidity is a strength, profitability remains a critical challenge.
Loading financial metrics...
Company is burning $1.3M per quarter with $4.3M in cash. Approximately 3.2 quarters of runway at current burn rate.
Company posted a loss of $-2.1M over the last year, representing 359.4% of revenue.
Debt of $18.3M is 4.3x the company's cash position of $4.3M.
Operating cash flow has been negative for 3 consecutive quarters, burning $5.4M over the last year.
Revenue growing at 10.8% YoY, outpacing typical market growth rates.
Gross margin expanded by 5.8 percentage points, indicating improved pricing power or cost efficiency.
Strong gross margin of 55.0% reflects healthy unit economics.
Excellent liquidity with current ratio of 4.2x ensures operational stability.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Medical Devices companies of a similar size
Based on 2025-Q3 (September 30, 2025)